Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
NASH - Nonalcoholic Steatohepatitis: early-phase trial registry
7 of 29 indexed NASH - Nonalcoholic Steatohepatitis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #552 of 28,707 conditions by registered trial count.
29 US clinical trials · 7 currently recruiting · #552 of 28,707 conditions by registered trial count
NASH - Nonalcoholic Steatohepatitis: 29 US clinical trials tracked, 7 recruiting.
NASH - Nonalcoholic Steatohepatitis is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Madrigal Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition nash-nonalcoholic-steatohepatitis
OPEN 7 | RECR 24% | LATE 4 | EARLY 13 | RANK #552 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Burnout, Professional (24% recruiting · 29 trials)
NASH - Nonalcoholic Steatohepatitis lists 7 open slots (24% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for NASH - Nonalcoholic Steatohepatitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
NASH - Nonalcoholic Steatohepatitis is recruiting below its size-band peers.
7 of 29 indexed trials (24.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of NASH - Nonalcoholic Steatohepatitis trials is spread across many organizations.
Madrigal Pharmaceuticals accounts for 2 of 29 trials (6.9%). 25 distinct sponsors appear on at least one study for this condition label.
-
Typical NASH - Nonalcoholic Steatohepatitis enrolment sits around 80 participants.
Median target enrolment is 80 among the 29 trials that report a genuine target (sentinel values excluded). 16 of those (55.2%) plan for fewer than 100 participants.
-
NASH - Nonalcoholic Steatohepatitis research is mostly interventional.
23 interventional and 6 observational studies make up this index (79.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
29 total, page 1 of 1
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Akero Therapeutics
NCT06528314
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
Inventiva Pharma
NCT04849728
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Perspectum
NCT04054310
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
Mayo Clinic
NCT04232566
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
Massachusetts General Hospital
NCT04833140
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
University of Minnesota
NCT03587831
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis
Milton S. Hershey Medical Center
NCT06195943
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals
NCT03900429
LITMUS Imaging Study
University of Oxford
NCT05479721
Nonalcoholic Fatty Liver Disease in HIV Database
Johns Hopkins University
NCT05023044
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
Hanmi Pharmaceutical Company Limited
NCT04505436
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
Akero Therapeutics
NCT05039450
Statins for the Treatment of NASH
Mayo Clinic
NCT04679376
Tocotrienol Against the Progression of End Stage Liver Disease
Chandan Sen
NCT02581085
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Indiana University
NCT04383951
Novel MRE Technique to Assess a Risk Factor for Liver Cancer
Natalie Torok
NCT05165446
Hepatic Energy Fluxes in NASH and NAS Patients
University of Minnesota
NCT03997422
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
Cirius Therapeutics
NCT02784444
The Liver in the World Trade Center Health Program General Responder Cohort and Controls
Icahn School of Medicine at Mount Sinai
NCT03858920
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
NGM Biopharmaceuticals
NCT03912532
DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis
Terns
NCT05415722
Quantifying Body Composition and Liver Disease in Children Using Free-Breathing MRI and MRE
University of California, Los Angeles
NCT04591106
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
Madrigal Pharmaceuticals
NCT04643795
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
Rivus Pharmaceuticals
NCT04874233
Effect of Vitamin E on Non-Alcoholic Fatty Liver Disease
Jeffrey Browning
NCT02690792
A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects
Enanta Pharmaceuticals
NCT03783897
A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
Lipocine
NCT04685993
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis
89bio
NCT05022693
Study of Gemcabene in Adults With FPLD
Elif Oral
NCT03508687
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 9 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on NASH - Nonalcoholic Steatohepatitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on NASH - Nonalcoholic Steatohepatitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this NASH - Nonalcoholic Steatohepatitis page
29 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 NASH - Nonalcoholic Steatohepatitis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Madrigal Pharmaceuticals sponsors the most NASH - Nonalcoholic Steatohepatitis trials on record, review their full trial history before evaluating a specific study. See Madrigal Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This NASH - Nonalcoholic Steatohepatitis condition card totals 29 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.